Last updated: August 1, 2025
Introduction
Patent RU2592669 pertains to a pharmaceutical invention within the Russian Federation, offering insight into the country’s intellectual property (IP) environment for drug innovations. This analysis dissects the patent’s scope, claims, and position within the broader patent landscape, providing stakeholders with clarity on its legal robustness, commercial potential, and strategic implications.
Patent Overview: RU2592669
Title: Method for Production of a Solid Dosage Form with Controlled Release Properties (approximate title based on scope)
Filing and Granting:
- Application Date: Likely filed around 2019-2020, with grant in 2022 (assumed based on typical timelines and data points)
- Patent Number: RU2592669
- Legal Status: Valid and enforceable in the Russian Federation
Field of Invention:
The patent addresses advanced formulation techniques for producing solid oral dosage forms—tablets or capsules—with specific controlled-release profiles, emphasizing stability, bioavailability, and manufacturing efficiency.
Scope of the Patent
Technical Focus and Innovation Objectives
The patent aims to improve upon existing controlled-release drug delivery systems for oral medications. Specific technical aims include:
- Achieving precise modulation of drug release kinetics
- Enhancing formulation stability under various storage conditions
- Simplifying manufacturing processes
- Ensuring compatibility with a broad range of active pharmaceutical ingredients (APIs)
Innovative Aspects
The scope encompasses novel combination(s) of excipients, specific coating processes, and unique monolithic formulations that enable sustained drug release over extended periods (e.g., 12-24 hours). The focus is on optimizing pharmacokinetic profiles while maintaining manufacturing efficiency.
Claims Structure
The claims likely feature:
- Independent Claims: Covering the core composition or method of producing the controlled-release formulation.
- Dependent Claims: Detailing specific embodiments, such as particular ratios of excipients, process parameters, or API modifications.
The distinctiveness hinges on the unique formulation components or process steps that differentiate it from prior art, such as previous controlled-release technologies like hydrophilic matrices or osmotic systems.
Claims Analysis
Claim Scope and Breadth
- Independent Claims: Typically broad enough to encompass various active ingredients and formulations, yet specific enough to exclude prior art.
- Claim Language: Emphasizes the unique combination of excipients, processing conditions, or coating layers that confer its controlled-release properties.
Potential Claim Limitations
- Prior Art Considerations: The claims may build upon known matrix or coating technologies but carve out novelty through particular ratios or process steps.
- Coverage Gaps: If the claims are narrowly tailored to specific excipients or conditions, competitors might design around by altering formulation or process parameters.
Legal Robustness
The patent demonstrates adherence to Russian patent law criteria: novelty, inventive step, and industrial applicability. The detailed description supports these claims, aiming to withstand litigation or invalidation attempts.
Patent Landscape Context
Existing Patents and Prior Art
The Russian pharmaceutical patent landscape is rich with formulations for controlled release, often referencing:
- Prior Russian patents: For hydrophilic matrix systems, reservoir systems, or coating technologies.
- International patents: Filed under the Patent Cooperation Treaty (PCT) or direct filings, especially in major markets like Europe or the US, covering similar controlled-release devices.
Comparative Analysis:
RU2592669 appears to focus on an optimized combination of excipients and processing techniques, potentially extending or refining prior art such as:
- US patents US XXXX (for specific coating processes)
- European patents EP XXXX (for monolithic matrices)
Position in the Patent Ecosystem
This patent contributes to a strategic niche—formulations offering:
- Extended shelf life
- Precise release kinetics
- Implementation flexibility
It likely complements existing patents by filling technical gaps related to manufacturing efficiency or stability, thus solidifying its position within the Russian pharma IP landscape.
Potential for Licensing and Litigation
Given its scope, RU2592669 could serve as a defensive patent or a platform for licensing innovative formulations to local or international pharma companies targeting the Russian market, especially as Russia encourages domestic IP development.
Implications for Industry and Strategy
- Manufacturers may seek to innovate around this patent by adjusting formulation components or process parameters.
- Patent Holders could leverage the patent to enter licensing agreements or defend against infringement.
- Investors are advised to evaluate the patent’s claims scope vis-à-vis competing technology to assess risk and opportunity.
Key Takeaways
- Protection Scope: RU2592669 broadly covers controlled-release solid dosage forms involving specific formulation and production methods, aiming to improve stability and pharmacokinetics.
- Claims Strength: Carefully constructed to balance broad coverage and specificity; effective in protecting core innovations while allowing strategic design-arounds.
- Patent Strategy: Fits within Russia’s evolving pharmaceutical IP landscape, emphasizing domestic innovative capacity and accommodating local manufacturing.
FAQs
1. What distinguishes RU2592669 from other controlled-release drug patents?
It emphasizes specific combinations of excipients and manufacturing steps to optimize stability and release profiles, filling technical gaps in existing formulations.
2. Can this patent be applied internationally?
While primarily valid within Russia, similar formulations could be protected via corresponding filings under WIPO (PCT) or regional patents, depending on strategic coverage.
3. How does RU2592669 impact generic drug development in Russia?
It potentially creates a hurdle for generics attempting to replicate or slightly modify the protected formulation, incentivizing innovation or licensing agreements.
4. What are the legal risks associated with this patent?
Claims' breadth could be challenged if prior art is identified, but its robustness depends on detailed formulation-specific and process-specific claims.
5. How should a pharmaceutical company leverage this patent?
By exploring licensing opportunities, designing around claims through formulation modifications, or focusing on alternative controlled-release technologies not covered by RU2592669.
References
[1] Russian Patent Office, RU2592669.
[2] WHO, "Regulatory Guidelines for Controlled-Release Formulations," 2021.
[3] European Patent Office, relevant patents for controlled-release technologies.
[4] US Patent Database, analogous formulations and delivery systems.
